Advertisement


Rami Manochakian, MD, FASCO, on Tarlatamab vs Chemotherapy for Second-Line Treatment of SCLC: Expert Point of View

2025 ASCO Annual Meeting

Advertisement

Rami Manochakian, MD, FASCO, of Mayo Clinic Florida, offers his thoughts on findings from the primary analysis of the phase III DeLLphi-304 trial, which compared tarlatamab-dlle, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, with chemotherapy as a second-line treatment of patients with small cell lung cancer (SCLC) (LBA8008). 



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
DELPHI-304 trial is a randomized controlled phase 3 trial comparing tarlatamab to chemotherapy in the second-line treatment of patients with small cell lung cancer who had disease progression after first-line chemotherapy, with or without a checkpoint inhibitor. Tarlatamab is a bispecific T-cell engager that targets DLL3 and CD3 and was approved in the second-line treatment and beyond of advanced small cell lung cancer based on DELPHI-301, which showed a very good response rate. DELPHI-304, of which the results were reported by the investigators at the ASCO 2025 Annual Meeting, also had an associated manuscript published in the New England Journal of Medicine. The study showed impressive, significant improvement in overall survival—statistically significant and, more importantly, meaningful clinical improvements. The hazard ratio was 0.6. There was a median overall survival improvement of more than five months, from 8.3 to 11.6 months. Other clinical outcomes that were reported included a response rate of about 35%. There was also improvement in progression-free survival. Kudos also to the investigators who reported patient outcomes, and there was a significant improvement in patient symptoms, particularly dyspnea and cough, with tarlatamab. When it comes to safety profile, tarlatamab had overall a better safety profile. There were significantly fewer grade 3 or above adverse events compared to chemotherapy. When it comes to the unique side effects—CRS (cytokine release syndrome) and ICANS—they were mostly grade 1 or 2 and managed fairly well with minimal issues, except maybe one case of ICANS. Why is this study important? Very important, because it's the first study ever to show a drug that has a better overall survival benefit compared to chemotherapy in the second-line setting treatment of small cell lung cancer. This is a standard-of-care treatment. From now on, if not already, I will be using it in clinic. I'm already using it. A couple of things to make sure we address on this drug, tarlatamab. We do know that there are some logistics to administering the drug—maybe in the hospital for the first couple of doses, as was done initially in the trial, and then it was adjusted. The reason is to watch for those side effects. Although they're rare—the reactions, the CRS—it requires some extra time of observation after the infusion. But I think as we evolve, we're seeing that has been more doable, and the study itself showed that actually observing in outpatient is doable. And then of course, more importantly, even though the percentage of higher-grade adverse events was lower with tarlatamab, we still owe it to our patients to monitor closely, to optimize and do everything to support them, and to treat those in a timely manner.

Related Videos

Leukemia

Mazyar Shadman, MD, PhD, on Doublet for Treatment-Naive CLL/SLL

Mazyar Shadman, MD, PhD, of Fred Hutchinson Cancer Center and the University of Washington, presents results from arm D of the SEQUOIA trial, which evaluated the combination of zanubrutinib and venetoclax in treatment-naive patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (Abstract 7009). 

CNS Cancers

Manmeet Singh Ahluwalia, MD, MBA, FASCO, on Liquid Biopsy in Glioblastoma

Manmeet Singh Ahluwalia, MD, MBA, FASCO, of Miami Cancer Institute, Baptist Health South Florida, discusses the ongoing LIBERATE trial, which is evaluating safety and technical efficacy of transcranial MR-guided microbubble-enhanced transcranial focused ultrasound for increasing blood circulating tumor and cell-free DNA levels in adults with glioblastoma (Abstract TPS2094). 

Breast Cancer

Nicholas C. Turner, MD, PhD, on Treating Emergent ESR1 Mutations in Advanced Breast Cancer

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, presents findings from the phase III, double-blind ctDNA-guided SERENA-6 trial, which evaluated the combination of camizestrant plus a CDK4/6 inhibitor to treat emergent ESR1 mutations during first-line endocrine therapy for patients with HR-positive, HER2-negative advanced breast cancer (LBA4). 

Lung Cancer

Jamie E. Chaft, MD, FASCO, on Resectable EGFR-Mutated NSCLC: NeoADAURA Results

Jamie E. Chaft, MD, FASCO, of Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, reviews results of the NeoADAURA trial, which looked at neoadjuvant osimertinib with or without chemotherapy vs chemotherapy alone in patients with resectable EGFR-mutated non–small cell lung cancer (NSCLC) (Abstract 8001). 

Gynecologic Cancers

Alicia Latham, MD, MS, on Using ctDNA to Detect Endometrial Cancer

Alicia Latham, MD, MS, of Memorial Sloan Kettering Cancer Center, discusses the feasibility of using Pap-derived ctDNA for the detection of sporadic and Lynch syndrome–associated endometrial cancer (Abstract 10503). 

Advertisement

Advertisement




Advertisement